Related references
Note: Only part of the references are listed.Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors
Daniel Q. Huang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)
Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
Xiaoqiang Yin et al.
BIOSCIENCE REPORTS (2022)
Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study
Shukui Qin et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau et al.
LANCET ONCOLOGY (2022)
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2022)
Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment
Leonardo Stella et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2022)
Oncogenic signaling pathway mediated by Notch pathway-related genes induces immunosuppression and immunotherapy resistance in hepatocellular carcinoma
Peng Ma et al.
IMMUNOGENETICS (2022)
Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives
Masayuki Ueno et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2022)
Epidemiologic and socioeconomic factors impacting hepatitis B virus and related hepatocellular carcinoma
Bipul Gnyawali et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2022)
Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development
Qian Wei et al.
BIOCHEMICAL JOURNAL (2022)
Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities
Carmelo Laface et al.
CANCERS (2022)
Hyperthermic intraperitoneal chemotherapy and colorectal cancer: From physiology to surgery
Giorgio Ammerata et al.
WORLD JOURNAL OF CLINICAL CASES (2022)
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A for Nonrandomized, Open-label, Phase II Trial
Jianming Xu et al.
CLINICAL CANCER RESEARCH (2021)
Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
Philippe Rochigneux et al.
CANCERS (2021)
Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms
Mariarita Laforgia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial
Masatoshi Kudo et al.
LIVER CANCER (2021)
First-in-man phase I clinical trial evaluating TTI-101, an orally bioavailable, small molecule inhibitor of STAT3, in patients with advanced solid tumors.
Apostolia Maria Tsimberidou et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
Masatoshi Kudo et al.
JOURNAL OF HEPATOLOGY (2021)
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
Zhenggang Ren et al.
LANCET ONCOLOGY (2021)
Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art
Carmelo Laface et al.
CANCERS (2021)
Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
Yuan-Hung Kuo et al.
FRONTIERS IN ONCOLOGY (2021)
A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117.
Masatoshi Kudo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials
Donghua Shi et al.
CLINICAL CANCER RESEARCH (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas
Manling Huang et al.
CLINICAL CANCER RESEARCH (2020)
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
Cheol-Hyung Lee et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Loco-Regional and Systemic Chemotherapies for Hepato-Pancreatic Tumors: Integrated Treatments
Girolamo Ranieri et al.
CANCERS (2020)
Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial
Hanren Dai et al.
ONCOIMMUNOLOGY (2020)
Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study
Girolamo Ranieri et al.
FRONTIERS IN ONCOLOGY (2020)
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Yongshuai Jiang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Shukui Qin et al.
FUTURE ONCOLOGY (2019)
Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
Josep M. Llovet et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune cell therapy for hepatocellular carcinoma
Eishiro Mizukoshi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling
Zhaoyun Zong et al.
FRONTIERS IN IMMUNOLOGY (2019)
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
M. Moehler et al.
ONCOIMMUNOLOGY (2019)
Immune Checkpoint Inhibitors: Basics and Challenges
Bin Li et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Mechanisms Controlling PD-L1 Expression in Cancer
Jong-Ho Cha et al.
MOLECULAR CELL (2019)
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J. Harding et al.
CLINICAL CANCER RESEARCH (2019)
Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC
Roser Pinyol et al.
CLINICAL CANCER RESEARCH (2019)
Epidemiology and Management of Hepatocellular Carcinoma
Laura Kulik et al.
GASTROENTEROLOGY (2019)
Contribution of regulatory T cells to cancer: A review
Masoud Najafi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang et al.
MOLECULAR CANCER (2019)
Adoptive cell transfer therapy for hepatocellular carcinoma
Renyu Zhang et al.
FRONTIERS OF MEDICINE (2019)
T-cell receptor-engineered T cells for cancer treatment: current status and future directions
Yu Ping et al.
PROTEIN & CELL (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Combination Cancer Immunotherapy in Hepatocellular Carcinoma
Masatoshi Kudo
LIVER CANCER (2018)
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Oncolytic virus immunotherapy: future prospects for oncology
Junaid Raja et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
Christopher J. LaRocca et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
Staging systems of hepatocellular carcinoma: A review
Sreeshma Tellapuri et al.
INDIAN JOURNAL OF GASTROENTEROLOGY (2018)
Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.
Anthony B. El-Khoueiry et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer
Min Xu et al.
EXPERIMENTAL CELL RESEARCH (2017)
Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein - Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma
Hidetoshi Nakagawa et al.
GASTROENTEROLOGY (2017)
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
Guoying Zhou et al.
GASTROENTEROLOGY (2017)
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Daniela Sia et al.
GASTROENTEROLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
Combination immunotherapy: a road map
Patrick A. Ott et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).
Zev A. Wainberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice
Kwang Hwa Jung et al.
CLINICAL CANCER RESEARCH (2017)
Targeting Notch3 in Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Perspectives
Catia Giovannini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Immunosuppressive cells in tumor immune escape and metastasis
Yang Liu et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2016)
Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma
Longhao Sun et al.
TUMOR BIOLOGY (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Immunity, tolerance and autoimmunity in the liver: A comprehensive review
Derek G. Doherty
JOURNAL OF AUTOIMMUNITY (2016)
Notch2 is a crucial regulator of self-renewal and tumorigenicity in human hepatocellular carcinoma cells
Wen-Rui Wu et al.
ONCOLOGY REPORTS (2016)
Mast cells positive to tryptase, endothelial cells positive to protease-activated receptor-2, and microvascular density correlate among themselves in hepatocellular carcinoma patients who have undergone surgery
Michele Ammendola et al.
ONCOTARGETS AND THERAPY (2016)
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma
Catia Giovannini et al.
ONCOTARGET (2016)
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
Yu Sawada et al.
ONCOIMMUNOLOGY (2016)
PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma
Eishiro Mizukoshi et al.
CANCER LETTERS (2015)
T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice
Christina Dargel et al.
GASTROENTEROLOGY (2015)
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
JOURNAL OF CLINICAL INVESTIGATION (2015)
NOTCH2 signaling confers immature morphology and aggressiveness in human hepatocellular carcinoma cells
Yoshihiro Hayashi et al.
ONCOLOGY REPORTS (2015)
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay et al.
SEMINARS IN CANCER BIOLOGY (2015)
Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients
Girolamo Ranieri et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
Lateral inhibition of Notch signaling in neoplastic cells
Kah Jing Lim et al.
ONCOTARGET (2015)
The 4 Notch receptors play distinct and antagonistic roles in the proliferation and hepatocytic differentiation of liver progenitors
Sara Ortica et al.
FASEB JOURNAL (2014)
Notch1 increases Snail expression under high reactive oxygen species conditions in hepatocellular carcinoma cells
H. S. Kim et al.
FREE RADICAL RESEARCH (2014)
Downregulation of Notch1 inhibits the invasion of human hepatocellular carcinoma HepG2 and MHCC97H cells through the regulation of PTEN and FAK
Yan-Jian Hu et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2014)
Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment
Girolamo Ranieri et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study
Gennaro Gadaleta-Caldarola et al.
ONCOLOGY LETTERS (2014)
Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma
Soomin Ahn et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2013)
Cytokine-induced killer cells promote antitumor immunity
Jingting Jiang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3β phosphorylation and p21 down-regulation in hepatocellular carcinoma
Catia Giovannini et al.
ONCOTARGET (2013)
Tryptase serum levels in patients suffering from hepatocellular carcinoma undergoing intra-arterial chemoembolization: Possible predictive role of response to treatment
Veronica Goffredo et al.
MOLECULAR AND CLINICAL ONCOLOGY (2013)
Gene-engineered T cells for cancer therapy
Michael H. Kershaw et al.
NATURE REVIEWS CANCER (2013)
Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
G. Ranieri et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice
Augusto Villanueva et al.
GASTROENTEROLOGY (2012)
Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
Fujimasa Tada et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Oncolytic virotherapy
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY (2012)
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy
Shannon M. McAuliffe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Notch1 binds and induces degradation of Snail in hepatocellular carcinoma
Seung-Oe Lim et al.
BMC BIOLOGY (2011)
Yttrium-90 (90Y) in the principal radionuclide therapies: An efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009)
Veronica Goffredo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors
C. Damiano Gadaleta et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism
Raphael Kopan et al.
CELL (2009)
A Phase II Study of Adoptive Immunotherapy Using Dendritic Cells Pulsed with Tumor Lysate in Patients with Hepatocellular Carcinoma
Daniel H. Palmer et al.
HEPATOLOGY (2009)
Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism
Catia Giovannini et al.
JOURNAL OF HEPATOLOGY (2009)
Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine
Karin Gustafsson et al.
CANCER RESEARCH (2008)
Deregulated expression of Notch receptors in human hepatocellular carcinoma
J. Gao et al.
DIGESTIVE AND LIVER DISEASE (2008)
Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma
Laura Gramantieri et al.
LIVER INTERNATIONAL (2007)
Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent
B Valzasina et al.
CANCER RESEARCH (2006)
Anchoring Notch genetics and biochemistry: Structural analysis of the ankyrin domain sheds light on existing data
OY Lubman et al.
MOLECULAR CELL (2004)
Serum Vascular Endothelial Growth Factor Concentrations in Hepatocellular Cancer Patients Undergoing Percutaneously Radiofrequency Thermal Ablation
C. Gadaleta et al.
JOURNAL OF CHEMOTHERAPY (2004)
The role of Notch in tumorigenesis: Oncogene or tumour suppressor?
F Radtke et al.
NATURE REVIEWS CANCER (2003)
Share Paper
